KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBITDA (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EBITDA data on record, last reported at -$283.4 million in Q4 2025.

  • For Q4 2025, EBITDA fell 69.03% year-over-year to -$283.4 million; the TTM value through Dec 2025 reached $25.2 million, down 88.93%, while the annual FY2025 figure was $25.2 million, 88.93% down from the prior year.
  • EBITDA reached -$283.4 million in Q4 2025 per CRL's latest filing, down from $133.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $187.4 million in Q2 2022 and bottomed at -$283.4 million in Q4 2025.
  • Average EBITDA over 5 years is $105.5 million, with a median of $143.2 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 79.18% in 2021, then tumbled 226.15% in 2024.
  • A 5-year view of EBITDA shows it stood at $172.8 million in 2021, then fell by 5.21% to $163.8 million in 2022, then dropped by 18.86% to $132.9 million in 2023, then crashed by 226.15% to -$167.7 million in 2024, then tumbled by 69.03% to -$283.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$283.4 million in Q4 2025, $133.8 million in Q3 2025, and $100.1 million in Q2 2025.